Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 9/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13399966 | 0.81 | AURKA (0.49) | AURKACHEK1 | |
| SCHEMBL13399957 | 0.81 | AURKA (0.50) | AURKACHEK1AURKBKDM4EGAA | |
| SCHEMBL13399933 | 0.79 | AURKA (0.46) | AURKACHEK1AURKBKDM4EGAA | |
| SCHEMBL13399927 | 0.79 | AURKA (0.44) | AURKACHEK1AURKB | |
| SCHEMBL13399882 | 0.78 | AURKA (0.66) | AURKA | |
| SCHEMBL13399885 | 0.78 | AURKA (0.50) | AURKACHEK1AURKBKDM4EGAA | |
| SCHEMBL13399952 | 0.77 | MAP2K1 (0.57) | AURKACHEK1 | |
| SCHEMBL13399970 | 0.77 | MAP2K1 (0.57) | AURKAKDM4E | |
| SCHEMBL13399888 | 0.77 | CHEK1 (0.44) | AURKACHEK1ROCK2AURKBKDM4E | |
| SCHEMBL13399932 | 0.77 | AURKA (0.43) | AURKACHEK1AURKBKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006252-B2 | Fused multicyclic compounds as protein kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2015-04-14 | — | — | US | disclosed |
| US-9006252-B2 | Fused multicyclic compounds as protein kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2015-04-14 | — | — | US | disclosed |
| EP-2331530-B1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (CN) | 2013-08-21 | — | — | EP | disclosed |
| WO-2010036629-A2 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-01 | — | — | WO | disclosed |
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-01 | — | — | US | disclosed |
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, AURKB | AURKA 2/4885CHEK1 112/4885ROCK2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.